Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Opening the lead generation toolbox

Nature Reviews Drug Discovery volume 13, pages 3–4 (2014)Cite this article

Subjects

Early-stage drug discovery is rapidly evolving into an endeavour in which scientific research communities in both the public and private sectors are finding new ways to share knowledge, expertise and resources. Here, we discuss some of the challenges for such collaborations and highlight examples in which traditional barriers such as intellectual property concerns have been addressed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug. Discov. 9, 203–213 (2010).

    Article  CAS  Google Scholar 

  2. Mullard. A. European Lead Factory opens for business. Nature Rev. Drug Discov. 12, 173–175 (2013).

    Article  Google Scholar 

  3. Johnston, K. L. et al. Overcoming the challenges of drug discovery for neglected tropical diseases: The A•WOL experience. J. Biomol. Screen. http://dx.doi.org/10.1177/1087057113511270 (2013).

  4. Kogej, T. et al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca–Bayer Pharma AG case. Drug Discov. Today. 18, 1014–1024 (2013).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, Cheshire, UK

    Peter B. Simpson

  2. Lankenau Institute for Medical Research, Chemical Genomics Center, 100 East Lancaster Avenue, 19096, Pennsylvania, USA

    Melvin Reichman

Authors
  1. Peter B. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melvin Reichman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Peter B. Simpson or Melvin Reichman.

Ethics declarations

Competing interests

P.B.S. is an employee of AstraZeneca and M.R. is an employee of the Lankenau Institute for Medical Research Chemical Genomics Center.

Related links

Related links

FURTHER INFORMATION

Double-blinded Drug Discovery

Grants4Targets

Johns Hopkins Brain Science Institute NeuroTranslational Program

MedChemica

Open Innovation Drug Discovery

WIPO Re:Search

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, P., Reichman, M. Opening the lead generation toolbox. Nat Rev Drug Discov 13, 3–4 (2014). https://doi.org/10.1038/nrd4202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4202

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research